Repotrectinib Market Latest Technological Developments Report by 2034
Repotrectinib is a next-generation tyrosine kinase inhibitor (TKI) developed to target specific genetic mutations, particularly in cases of non-small cell lung cancer (NSCLC) and other solid tumors. It has gained attention due to its efficacy in patients with ROS1-positive NSCLC, a subset of lung cancer characterized by a mutation in the ROS1 gene. Repotrectinib's unique ability to cross the...
0 Distribuiri
56 Views
0 previzualizare